CSL's plasma success bodes well for market and competitors
This article was originally published in Scrip
Executive Summary
CSL's revenue from plasma proteins and recombinant products rose by 38% to A$3.7 billion ($3.05 billion) in the year ending June 30th, helping to drive total revenue up by 32% to A$5.04 billion.